BLOOD PRESSURE PROCEDURE
Benefits and risks
The renal denervation blood pressure procedure helps reduce high blood pressure (hypertension),*1–3 which is shown to lower your risk of heart attacks, strokes, and other serious health problems.4
Reducing hypertension can lower some of your health risks.
Reducing blood pressure by 10 mmHg can lower your risk of:
heart failure4
↓28%
cardiovascular events4
↓20%
stroke4
↓27%
Benefits
Beyond another daily blood pressure pill
While it may not affect how many medications you take, the renal denervation blood pressure procedure helps reduce high blood pressure without adding another pill to your daily regimen.1,2
Management beyond blood pressure medications
The renal denervation blood pressure procedure is proven to safely help lower blood pressure in people who are taking blood pressure medication and those who are not.1,2
-16.7
mmHg
blood pressure reduction in a three-year study of people who received the Symplicity procedure3
Risks
What are the risks of the renal denervation blood pressure procedure?
The renal denervation blood pressure procedure, just like any medical procedure, has risks. It's important to talk with your doctor about the benefits and risks.
The potential risks as well as complication rates for the renal denervation blood pressure procedure are similar to those associated with other interventional procedures.
See how it works.
Get more details about the renal denervation blood pressure procedure.
Always follow the instructions specified by your doctor or the nursing staff. Always follow the discharge instructions provided by your physician after your procedure.
References
1
Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. June 9, 2018;391(10137):2346–2355.
2
Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. May 2, 2020;395(10234):1444–1451.
3
Mahfoud F, Mancia G, Schmieder R, et al. Blood pressure and MACE reductions after renal denervation: 3-year Global Symplicity Registry results. Presented at PCR e-course 2022.
4
Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and metaanalysis. Lancet. March 5, 2016;387(10022):957–967.